Health campaigners accuse Philip Morris of misleading statements regarding FDA, impacting IQOS launch

From Investing.com: 2024-07-16 02:13:08

Health campaigners are accusing Philip Morris International of misleading statements regarding FDA decisions to disrupt the launch of its IQOS tobacco device in the US. Independent studies suggest a lower rate of smokers switching exclusively to IQOS compared to PMI claims. FDA is yet to make a decision on PMI’s applications.

The FDA previously rejected PMI’s claim that IQOS reduces health risks, lacking evidence. The agency approved selling an older version with reduced exposure to harmful chemicals. PMI has applied to renew exposure modification orders for 2023 and market a newer version. FDA decision pending, which could impact tax benefits and consumer perception.

Campaign groups cite ITC studies in Japan and Korea showing lower rates of smokers exclusively using IQOS than PMI claims. Dual use of cigarettes and IQOS may lead to increased tobacco consumption. PMI contends majority of its users have quit smoking, but independent studies refute this, highlighting potential flaws in government surveys.



Read more at Investing.com: Exclusive-Campaigners target Philip Morris’ flagship heated tobacco US launch By Reuters